Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2023.
-
Busy address KBO
10 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
UCB PHARMA from Anderlecht, company number BE0403096168, closed financial year 2025 with a result of € 4.2 billion after tax. For that financial year UCB PHARMA recorded revenue of € 4.6 billion and equity of € 16.2 billion. Compared with financial year 2024, the result moved from € 947.4 million to € 4.2 billion. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 19, 2026.
€ 16.2 billion
▲ 31% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 4.2 billion
▲ € 3.3 billion vs 2024
Profit after tax over the fiscal year.
€ 7.9 million
▼ 29% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 400 million paid out
9 % of the profit went to the shareholders, mostly to UCB SA (100 % of the shares). That is where the money ends up.
People and assets in 2025
1,960.6
▲ 214.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 291.3 million
▲ 17% vs 2024
€ 148,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 6.7 million
▲ 64% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2.1 billion
▼ 13% vs 2024
Loans from banks and other lenders, long and short.
€ 1.7 billion
▲ 78% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 117 days on average.
€ 72.7 million
▼ 29% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 3,295,211,826 | € 3,177,016,793 | € 4,211,459,762 | € 4,622,639,386 | ▲ 10% |
| Profit after taxes | € 948,100,009 | € 938,115,520 | € 947,428,300 | € 4,239,651,764 | ▲ € 3.3 billion |
| Equity | € 11,209,624,353 | € 11,797,739,873 | € 12,395,168,174 | € 16,234,819,937 | ▲ 31% |
| Total debts | € 3,320,620,353 | € 3,336,348,470 | € 3,932,063,198 | € 4,371,077,190 | ▲ 11% |
| Cash | € 16,847,177 | € 7,687,095 | € 11,059,144 | € 7,874,572 | ▼ 29% |
| Land & buildings | € 177,261,984 | € 191,007,094 | € 203,674,814 | € 412,941,560 | ▲ 103% |
| Retained profit | € 3,404,850,543 | € 3,992,966,063 | € 4,590,394,364 | € 8,430,046,127 | ▲ 84% |
| Dividend | € 300,000,000 | € 350,000,000 | € 350,000,000 | € 400,000,000 | ▲ 14% |
| Bank debt | € 2,205,440,402 | € 2,305,492,651 | € 2,409,012,849 | € 2,090,135,731 | ▼ 13% |
| Balance sheet total | € 14,568,296,839 | € 15,197,496,330 | € 16,414,794,946 | € 20,742,385,083 | ▲ 26% |
| Employees (FTE) | 1,371.1 | 1,464.4 | 1,746.4 | 1,960.6 | ▲ 214.2 |
Key figures of UCB PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to UCB PHARMA?
What happened at UCB PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Jean-Christophe TELLIER stepped down as director. NBB
- Kirsten LUND-JÜRGENSEN stepped down as director. NBB
- Caroline VANCOILLIE stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 4.2 billion (▲ € 3.3 billion vs 2024). Source: NBB ↗
- Jean-Christophe TELLIER became a director. NBB
- New establishment in Leuven. KBO
- Kirsten LUND-JÜRGENSEN became a director. NBB
- Caroline VANCOILLIE became a director. NBB
In short
From € 948.1 million profit in 2022 to € 4.2 billion profit in 2025.
Paid € 248.9 million in corporate taxes since 2022.
Best year ever: 2025, with € 4.2 billion profit.
Paid out € 1.4 billion in dividends to the owners in total.
Management
The shares are held by UCB SA (100%) and UCB Fipar SA (0%). It owns 100% of UCB Belgium, 100% of UCB Pharma Oy, 100% of UCB Pharma B.V., 100% of UCB Farchim SA (AG - Ltd), 100% of UCB Pharma A.S. and 100% of UCB Nordic AS itself.
Directors
According to the 2025 annual accounts
Jean-Christophe TELLIER
Chairman of the board
Also active at: UCB Fipar, UCB Ventures, UCB Ventures Belgium
since 2023 · until 2029
Kirsten LUND-JÜRGENSEN
Director
since 2022 · until 2028
since 2022 · until 2028
Shareholders
100%
0%
Participations
100%
UCB Pharma Oy
100%
UCB Pharma B.V.
100%
UCB Farchim SA (AG - Ltd)
100%
UCB Pharma A.S.
100%
UCB Nordic AS
100%
100%
UCB Holdings, Inc.
100%
UCB Pharma Ab
100%
UCB Pharma GmbH Austria
100%
UCB GmbH
94.8%
Establishments
Establishment units
Physical locations of this company
Researchdreef 60
1070 Anderlecht
Chemin du Foriest /
1420 Braine-l'Alleud
Active since 20 December 2006
Gaston Geenslaan 14
3001 Leuven
Active since 1 March 2023
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 10 companies are registered at this address.
All companies at this address →UCB Belgium same network
U C B same network
UCB Fipar same network
Fondation Emmanuel Janssen
UCB BIOPHARMA same network
€ 3.6 billion revenue · 2025
+5 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0403.096.168
- VAT number
- BE 0403.096.168
- Registered office
- Researchdreef 60, 1070 Anderlecht
- Names & denominations
- UCB PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 1 February 1968
- Peppol
- Active · Active since 2 Dec 2025
- Activities · NACE
Vervaardiging van geneesmiddelen
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten